Olga Göransson

Olga Göransson

Auto-generated profile, based on publicly available information

Olga Göransson

Department of Experimental Medical Science, Lund University, Lund, Sweden

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2004 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
Jose M LizcanoJose M Lizcano
Jose M Lizcano
OGOlga Göransson
Olga Göransson
RTRachel Toth
Rachel Toth
MDMaria Deak
Maria Deak
NMNick A Morrice
Nick A Morrice
DADario R Alessi
Dario R Alessi
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 August 2013 in Cell Metabolism
Verified
Journal Article
Closed access
RMRémi Mounier
Rémi Mounier
MTMarine Théret
Marine Théret
LALudovic Arnold
Ludovic Arnold
SCSylvain Cuvellier
Sylvain Cuvellier
LBLaurent Bultot
Laurent Bultot
BCBénédicte Chazaud
Bénédicte Chazaud

1 November 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
OGOlga Göransson
Olga Göransson
AMAndrew McBride
Andrew McBride
SHSimon A. Hawley
Simon A. Hawley
FRFiona A. Ross
Fiona A. Ross
NSNatalia Shpiro
Natalia Shpiro
KSKei Sakamoto
Kei Sakamoto
We have studied the mechanism of A-769662, a new activator of AMP-activated protein kinase (AMPK). Unlike other pharmacological activators, it directly activates native rat AMPK by mimicking both effects of AMP, i.e. allosteric activation and inhibition of dephosphorylation. We found that it has no effect on the isolated α subunit kinase domain, with or without the associated autoinhibitory domain, or on interaction of glycogen with the β subunit glycogen-binding domain. Although it mimics actions of AMP, it has no effect on binding of AMP to the isolated Bateman domains of the γ subunit. The addition of A-769662 to mouse embryonic fibroblasts or primary mouse hepatocytes stimulates phosphorylation of acetyl-CoA carboxylase (ACC), effects that are completely abolished in AMPK-α1–/–α2–/– cells but not in TAK1–/– mouse embryonic fibroblasts. Phosphorylation of AMPK and ACC in response to A-769662 is also abolished in isolated mouse skeletal muscle lacking LKB1, a major upstream kinase for AMPK in this tissue. However, in HeLa cells, which lack LKB1 but express the alternate upstream kinase calmodulin-dependent protein kinase kinase-β, phosphorylation of AMPK and ACC in response to A-769662 still occurs. These results show that in intact cells, the effects of A-769662 are independent of the upstream kinase utilized. We propose that this direct and specific AMPK activator will be a valuable experimental tool to understand the physiological roles of AMPK.

1 August 2004 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
KSKei Sakamoto
Kei Sakamoto
OGOlga Göransson
Olga Göransson
DHDavid Grahame Hardie
David Grahame Hardie
DADario R. Alessi
Dario R. Alessi
Activation of AMP-activated protein kinase (AMPK) by exercise and metformin is beneficial for the treatment of type 2 diabetes. We recently found that, in cultured cells, the LKB1 tumor suppressor protein kinase activates AMPK in response to the metformin analog phenformin and the AMP mimetic drug 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR). We have also reported that LKB1 activates 11 other AMPK-related kinases. The activity of LKB1 or the AMPK-related kinases has not previously been studied in a tissue with physiological relevance to diabetes. In this study, we have investigated whether contraction, phenformin, and AICAR influence LKB1 and AMPK-related kinase activity in rat skeletal muscle. Contraction in situ, induced via sciatic nerve stimulation, significantly increased AMPKα2 activity and phosphorylation in multiple muscle fiber types without affecting LKB1 activity. Treatment of isolated skeletal muscle with phenformin or AICAR stimulated the phosphorylation and activation of AMPKα1 and AMPKα2 without altering LKB1 activity. Contraction, phenformin, or AICAR did not significantly increase activities or expression of the AMPK-related kinases QSK, QIK, MARK2/3, and MARK4 in skeletal muscle. The results of this study suggest that muscle contraction, phenformin, or AICAR activates AMPK by a mechanism that does not involve direct activation of LKB1. They also suggest that the effects of excercise, phenformin, and AICAR on metabolic processes in muscle may be mediated through activation of AMPK rather than activation of LKB1 or the AMPK-related kinases.

4 August 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
KPKashyap Patel
Kashyap Patel
MFMarc Foretz
Marc Foretz
AMAllison Marion
Allison Marion
DCDavid G. Campbell
David G. Campbell
RGRobert Gourlay
Robert Gourlay
KSKei Sakamoto
Kei Sakamoto
LKB1 is a master kinase that regulates metabolism and growth through adenosine monophosphate-activated protein kinase (AMPK) and 12 other closely related kinases. Liver-specific ablation of LKB1 causes increased glucose production in hepatocytes in vitro and hyperglycaemia in fasting mice in vivo. Here we report that the salt-inducible kinases (SIK1, 2 and 3), members of the AMPK-related kinase family, play a key role as gluconeogenic suppressors downstream of LKB1 in the liver. The selective SIK inhibitor HG-9-91-01 promotes dephosphorylation of transcriptional co-activators CRTC2/3 resulting in enhanced gluconeogenic gene expression and glucose production in hepatocytes, an effect that is abolished when an HG-9-91-01-insensitive mutant SIK is introduced or LKB1 is ablated. Although SIK2 was proposed as a key regulator of insulin-mediated suppression of gluconeogenesis, we provide genetic evidence that liver-specific ablation of SIK2 alone has no effect on gluconeogenesis and insulin does not modulate SIK2 phosphorylation or activity. Collectively, we demonstrate that the LKB1–SIK pathway functions as a key gluconeogenic gatekeeper in the liver.

19 October 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMarc N. Wein
Marc N. Wein
YLYanke Liang
Yanke Liang
OGOlga Goransson
Olga Goransson
TSThomas B. Sundberg
Thomas B. Sundberg
JWJinhua Wang
Jinhua Wang
HKHenry M. Kronenberg
Henry M. Kronenberg
Parathyroid hormone (PTH) activates receptors on osteocytes to orchestrate bone formation and resorption. Here we show that PTH inhibition of SOST (sclerostin), a WNT antagonist, requires HDAC4 and HDAC5, whereas PTH stimulation of RANKL, a stimulator of bone resorption, requires CRTC2. Salt inducible kinases (SIKs) control subcellular localization of HDAC4/5 and CRTC2. PTH regulates both HDAC4/5 and CRTC2 localization via phosphorylation and inhibition of SIK2. Like PTH, new small molecule SIK inhibitors cause decreased phosphorylation and increased nuclear translocation of HDAC4/5 and CRTC2. SIK inhibition mimics many of the effects of PTH in osteocytes as assessed by RNA-seq in cultured osteocytes and following in vivo administration. Once daily treatment with the small molecule SIK inhibitor YKL-05-099 increases bone formation and bone mass. Therefore, a major arm of PTH signalling in osteocytes involves SIK inhibition, and small molecule SIK inhibitors may be applied therapeutically to mimic skeletal effects of PTH.